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Aims We aimed to evaluate the frequency, clinical features, and prognostic implications of cardiac arrest (CA) in tako-
tsubo syndrome (TTS).
...................................................................................................................................................................................................
Methods
and results
We reviewed the records of patients with CA and known heart rhythm from the International Takotsubo Registry.
The main outcomes were 60-day and 5-year mortality. In addition, predictors of mortality and predictors of CA
during the acute TTS phase were assessed. Of 2098 patients, 103 patients with CA and known heart rhythm during
CA were included. Compared with patients without CA, CA patients were more likely to be younger, male, and
have apical TTS, atrial fibrillation (AF), neurologic comorbidities, physical triggers, and longer corrected QT-interval
and lower left ventricular ejection fraction on admission. In all, 57.1% of patients with CA at admission had ven-
tricular fibrillation/tachycardia, while 73.7% of patients with CA in the acute phase had asystole/pulseless electrical
activity. Patients with CA showed higher 60-day (40.3% vs. 4.0%, P< 0.001) and 5-year mortality (68.9% vs. 16.7%,
P< 0.001) than patients without CA. T-wave inversion and intracranial haemorrhage were independently associated
with higher 60-day mortality after CA, whereas female gender was associated with lower 60-day mortality. In the
acute phase, CA occurred less frequently in females and more frequently in patients with AF, ST-segment elevation,
and higher C-reactive protein on admission.
...................................................................................................................................................................................................
Conclusions Cardiac arrest is relatively frequent in TTS and is associated with higher short- and long-term mortality. Clinical
and electrocardiographic parameters independently predicted mortality after CA.
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Introduction
Takotsubo syndrome (TTS) has long been considered a benign dis-
order.1 However, in recent years it has been uncovered that TTS can
be associated with different complications including cardiogenic
shock and life-threatening arrhythmias.2,3 Furthermore, sudden death
due to cardiac arrest (CA) is an underestimated threat in TTS.
Although 9% of TTS patients require resuscitation,4 CA in TTS has
not been comprehensively investigated.5 Life-threatening arrhyth-
mias, including bradyarrhythmias, ventricular fibrillation (VF), and
sustained/non-sustained ventricular tachycardia (VT) occur in 3.4–
12.2% of TTS patients.6–8 However, these reports are based on small
scale studies and do not directly explore CA in TTS. Indeed, TTS
may be the cause or the consequence of CA.9 The hyperadrenergic
milieu (endogenous or iatrogenic) associated with CA may trigger
TTS, and TTS features like corrected QT-interval (QTc) prolonga-
tion and diffuse myocardial oedema could lead to life-threatening
arrhythmias.10,11 Moreover, the long-term implications of CA in TTS
remain unclear. Although TTS is characterized by recovery of wall
motion abnormality and left ventricular ejection fraction (LVEF), it is
unclear whether successfully resuscitated TTS patients with CA sub-
sequently experience adverse outcomes. We therefore aimed to in-
vestigate the incidence and impact of CA in TTS.
Methods
Study population
The International Takotsubo Registry (InterTAK Registry, www.tako-
tsubo-registry.com) is a multicentre prospective and retrospective regis-
try13 encompassing 35 centres from 11 countries. Data for this study
were collected in accordance with institutional review board regulations.
From 2011 to 2017, a core team of investigators from University Hospital
Zurich reviewed the medical records of patients diagnosed with TTS be-
tween 1998 and 2017. The methods have been extensively reported in a
previous study.4,13
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In brief, TTS was diagnosed based on modified Mayo Clinic Diagnostic
Criteria4,14: (i) transient abnormal left ventricular wall motion beyond the
perfusion territory of a single epicardial coronary artery; (ii) no obstruct-
ive coronary artery disease or acute plaque rupture on angiography; (iii)
new electrocardiographic abnormalities or elevated cardiac troponins;
and (iv) no myocarditis. Exceptions included i) patients with coexisting
coronary artery disease that can not explain the wall motion abnormal-
ities ii) patients with wall motion abnormalities restricted to a single cor-
onary artery territory but matching all other criteria iii) patients who died
during the acute phase before recovery of wall motion abnormality was
documented. In patients with uncertain TTS diagnoses, the medical
records were reviewed by all core-team members, and a decision was
reached based on consensus.
The data of all TTS patients who underwent cardiopulmonary resusci-
tation (CPR) were reviewed, and those with confirmed CA and known
underlying heart rhythm were included in the present analysis. Cardiac
arrest was defined as the absence of a palpable pulse in an unconscious
patient requiring CPR to restore or attempt to restore systemic circula-
tion.15 Ventricular fibrillation, pulseless VT, or organized electric activity
other than VT [pulseless electrical activity (PEA) or asystole] on the elec-
trocardiogram registered during the acute event were recorded.16
Patients were divided into those presenting with CA (i.e. CA as the first
manifestation) and those subsequently developing CA during the acute
phase of TTS (i.e. no CA at presentation). A subgroup analysis was also
conducted including out-of-hospital vs. in-hospital CA. Information
regarding implantable/wearable cardioverter defibrillators and pace-
makers was recorded.
Study outcomes
Data regarding in-hospital complications and management were col-
lected. The main outcomes were 60-day and 5-year mortality.
Independent predictors of mortality and CA during the acute phase were
investigated. A 5-year landmark survival analysis was conducted for
patients who survived the first 60 days after TTS.
Statistical analysis
Continuous variables are presented as means and standard deviations or
medians and inter-quartile ranges (IQRs). Categorical variables are pro-
vided with percentages. Continuous variables were compared using the
Mann–Whitney U-test, whereas categorical variables were compared
using the Pearson v2 test or Fisher exact test. Kaplan–Meier curves were
established to provide survival estimates, and group differences were
assessed using the log-rank test. A univariable Cox regression analysis
was performed to identify predictors of 60-day mortality in patients with
CA. Covariates with P< 0.05 were included in a multivariable Cox regres-
sion model to identify independent predictors of 60-day mortality; miss-
ing values were replaced by multiple regression imputation. Another
univariable Cox regression analysis was performed to identify predictors
of CA in the acute phase among patients without CA at presentation. A
two-sided P-value <0.05 was considered statistically significant. Hazard
ratios are reported with 95% confidence intervals. All analyses were per-
formed with SPSS v23.0 (IBM Corp., Armonk, NY, USA), and graphs
were compiled with Prism 7 (GraphPad, La Jolla, CA, USA). The study is
registered on clinicaltrials.gov (NCT01947621).
Results
Clinical characteristics
During the study period, 2098 patients were included in the
InterTAK Registry (Figure 1 and Take home figure). Of the 170 (8.1%)
patients who received CPR, 46 patients without documented CA
were excluded. Of the remaining 124 patients with documented CA
(5.9% of overall cohort, 72.9% of patients requiring CPR), 103 had
data on the heart rhythm during CA (Figure 1).
Compared with patients without CA, those with CA were
younger and more frequently male (Table 1). Cardiac arrest patients
had higher heart rate, lower systolic blood pressure, longer QTc on
admission, higher maximal creatine kinase, and lower LVEF. They
more frequently had atrial fibrillation (AF: 21.1% vs. 6.4%, P< 0.001)
and apical TTS.
Cardiac arrest in relation to TTS onset
Eighty-four (81.6%) patients had CA at presentation and 19 (18.4%)
developed CA in the acute phase, as shown in Figure 1. Median onset
time of CA was 1 day (IQR 0–3 days) after TTS. The incidence of CA
in those without CA at presentation was 1.0% (19/1947). Compared
with patients with CA at presentation, those with CA in the acute
phase had higher peak brain natriuretic peptide (BNP) values, ST-seg-
ment elevation (Table 2) and PEA or asystole (73.7% vs. 42.9%;
Figure 1 and Take home figure) more frequently. Atrial fibrillation, ST-
segment elevation, and high C-reactive protein on admission were
associated with a higher risk of CA in the acute phase, whereas fe-
male sex was associated with a lower risk (see Supplementary mater-
ial online, Figure S1).
Outcomes
Cardiac arrest was associated with higher rates of in-hospital mortal-
ity, cardiogenic shock, catecholamine administration, and mechanical
ventilation (Table 1). Compared with patients without CA, those
with CA had higher 60-day mortality (40.3% vs. 4.0%, P< 0.001;
Figure 2) and 5-year mortality (68.9% vs. 16.7%, P< 0.001;
Supplementary material online, Figure S2). A 5-year outcome analysis
with a landmark set at 60 days after TTS index showed that patients
surviving CA had higher mortality than patients without CA (44.4%
vs. 13.3%, P< 0.001; Figure 2, and Take home figure). Among the CA
patients who survived the first 60 days, nine deaths occurred within
5 years: two (22.2%) cardiovascular deaths, three (33.3%) non-
cardiovascular deaths, and four (44.4%) deaths from unknown
causes. Among patients without CA, there were 10 (12.7%) cardio-
vascular deaths, 47 (59.5%) non-cardiovascular deaths, and 22
(27.8%) deaths from unknown causes.
In-hospital outcomes did not differ between patients with CA
at presentation or in the acute phase (Table 2), though the latter
showed a trend towards higher 60-day mortality (33.3% vs. 52.6%,
P= 0.12). Of the 12 CA patients who required implantable/wear-
able devices (implantable cardioverter defibrillator, 9; pacemaker,
2; and wearable cardioverter defibrillator, 1), 2 died during the 5-
year follow-up. Of the 58 CA patients discharged without a de-
vice, 10 died during the 5-year follow-up. Among the 67 patients
who underwent CPR but had unconfirmed CA or unknown heart
rhythm, 60-day mortality was 17.5%. Patients with out-of-hospital
and in-hospital CA had similar 60-day mortality (44% vs. 37%,
P= 0.29).
Predictors of outcomes
On univariable analysis, acute intracranial haemorrhage, T-wave in-
version on admission, and white blood cell count >10 103 cells/mL
2144 S. Gili et al.
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.were associated with higher 60-day mortality in patients with CA
than in patients without CA (Figure 3A). After adjusting for potential
confounders, T-wave inversion on admission and acute intracranial
haemorrhage were independently associated with higher 60-day
mortality after CA (Figure 3B). Female sex was associated with lower
mortality both on univariable and multivariable analysis. The results
remained unchanged even after excluding patients with intracranial
haemorrhage.
Discussion
This study found that (i) CA occurred in 5.9% of TTS patients; (ii) CA
was associated with a six-fold increase in short- and long-term mor-
tality; (iii) T-wave inversion on admission and acute intracranial haem-
orrhage were independently associated with 60-day mortality
following CA; (iv) in-hospital outcomes did not differ between
patients with CA at presentation and during the acute phase; and (v)
AF, ST-segment elevation, and high C-reactive protein on admission
were associated with a higher frequency of CA during the acute
phase, whereas female sex was associated with a lower frequency
(Take home figure).
The finding that CA is relatively common in TTS is important, as
TTS has historically been regarded as a benign condition. The
American Heart Association acknowledges the proarrhythmic
risk of TTS and includes TTS among the potential indications for
wearable cardioverter defibrillators. In contrast, TTS is not men-
tioned in the current European Society of Cardiology guidelines
for the management of ventricular arrhythmias.17,18 The CA inci-
dence (5.9%) in this study is consistent with previous reports.7,8,19
Only Pant et al.20 reported a lower incidence rate, but their diag-
noses were based on ICD-9 and not reviews of individual medical
records. Compared with patients without CA, those with CA
were younger, and less frequently female. Patients with CA have
lower LVEF, longer QTc, higher cardiac biomarker values, and
higher prevalence of apical TTS and AF. These findings suggest
that more severe cardiac dysfunction accompanies CA, which is in
agreement with the high prevalence of cardiogenic shock in these
patients. These differences in patients’ characteristics suggest that
different pathophysiological mechanisms are involved in patients
with and without CA.21 Cardiac arrest was more common among
TTS patients with physical triggers rather than emotional triggers,
which is consistent with previous observations.4 Cardiogenic
shock, though a consequence of CA,22 may also be a determinant
of CA, as hypotension is an important mechanism of CA in TTS.5
QTc prolongation in CA may be partly attributable to the drugs
administered, particularly amiodarone.23
2098 Patients in the InterTAK Registry
170 (8.1%) With initial resuscitation 
/ CPR due to absence of signs of 
circulation
1928 (91.9%) Without cardiac 
arrest
84 With cardiac arrest at 
presentation
19 With cardiac arrest in the acute 
phase
36 With PEA / Asystole
37 With ventricular fibrillation
11 With ventricular tachycardia
67 (3.2%) Were excluded
21 Cardiac arrest with unknown          
initial rhythm / ECG
11 Cardiogenic shock requiring
catecholamine boluses and 
ventilation
7 Epilepsy
7 Respiratory arrest
4 Transient asystole
4 Death due to complications of 
acute stroke
2 Septic shock
2 Haemorrhagic shock
2 Anaphylactic shock
1 Delayed sudden death of 
unclear etiology
6 Incomplete medical records
103 (4.9%) With cardiac arrest and 
known initial heart rhythm / ECG
14 With PEA / Asystole
3 With ventricular fibrillation
2 With ventricular tachycardia
Comparison
Comparison
Figure 1 Study design. CPR, cardiopulmonary resuscitation; ECG, electrocardiogram; PEA, pulseless electrical activity.
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..The higher 5-year mortality after CA was driven by not only a
higher 60-day mortality but also a steady increase in mortality after
the acute phase, as shown by the 5-year landmark analysis. This might
suggest that other factors beyond the acute myocardial dysfunction
are detrimental in these patients even after acute recovery. This is
consistent with a previous report linking life-threatening arrhythmias
during the index hospitalization with worse 1-year survival.12 In con-
trast, another study found no differences in 1-year survival between
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Table 1 Characteristics of takotsubo patients with and without cardiac arrest
TTS with CA and known
initial heart rhythm
TTS without CA
Characteristic N5 103 N5 1928 P-value
Demographics
Female sex, no./total no. (%) 85/103 (82.5) 1752/1928 (90.9) 0.005
Age (years) 61.9 ± 14.8 (N= 103) 67.3 ± 12.6 (N= 1928) <0.001
Symptoms and triggers, no./total no. (%)
Chest pain 27/75 (36.0) 1345/1759 (76.5) <0.001
Dyspnoea 29/75 (38.7) 816/1759 (46.4) 0.23
Physical trigger 62/103 (60.2) 652/1928 (33.8) <0.001
Emotional trigger 13/103 (12.6) 599/1928 (31.1) <0.001
ECG on admission
Sinus rhythm, no./total no. (%) 71/90 (78.9) 1590/1698 (93.6) <0.001
ST-segment elevation, no./total no. (%) 38/90 (42.2) 728/1698 (42.9) 0.90
ST-segment depression, no./total no. (%) 12/90 (13.3) 125/1698 (7.4) 0.038
T-wave inversion, no./total no. (%) 32/90 (35.6) 714/1698 (42.0) 0.22
Corrected QT (ms) 474.6 ± 46.8 (N= 81) 457.7 ± 47.3 (N= 1305) 0.001
Imaging and haemodynamic findings
Apical type, no./total no. (%) 84/103 (81.6) 1367/1928 (70.9) 0.020
LVEF (%)a 33.5 ± 9.8 (N= 96) 41.3 ± 11.4 (N= 1695) <0.001
Heart rate (beats/min) 91.2 ± 22.2 (N= 61) 87.2 ± 21.2 (N= 1503) 0.09
Systolic blood pressure (mmHg) 113.6 ± 25.0 (N= 62) 131.8 ± 28.4 (N= 1531) <0.001
LVEDP (mmHg) 21.2 ± 8.1 (N= 68) 21.7 ± 8.3 (N= 1102) 0.60
Neurologic and psychiatric disorders, no./total no. (%)
Acute neurologic disorders 13/97 (13.4) 149/1730 (8.6) 0.10
Acute intracranial bleeding 4/97 (4.1) 34/1730 (2.0) 0.15
Acute stroke/TIA 3/97 (3.1) 39/1730 (2.3) 0.59
Acute seizure 3/97 (3.1) 50/1730 (2.9) 0.91
Past or chronic neurologic disorders 20/94 (21.3) 314/1712 (18.3) 0.48
Acute psychiatric disorders 8/97 (8.2) 161/1727 (9.3) 0.72
Past or chronic psychiatric disorders 31/94 (33.0) 468/1711 (27.4) 0.24
Cardiac biomarkers, median (IQR)
Troponin admission, factor increase in ULNb 6.70 (2.00–19.64) N= 79 8.20 (2.68–23.61) N= 1466 0.20
Troponin maximum, factor increase in ULNb 12.07 (5.11–43.23) N= 84 14.04 (4.99–35.00) N= 1588 0.49
Creatine kinase admission, factor increase in ULN 1.00 (0.48–1.67) N = 76 0.87 (0.54–1.45) N= 1279 0.51
Creatine kinase maximum, factor increase in ULN 1.95 (0.73–4.42) N= 81 1.10 (0.65–1.87) N= 1319 <0.001
BNP admission, factor increase in ULNc 3.71 (1.33–10.15) N= 29 6.66 (2.35–18.22) N= 499 0.10
BNP maximum, factor increase in ULNc 7.51 (3.82–28.07) N= 39 10.22 (4.36–24.64) N= 640 0.61
In-hospital complications and management, no./total no. (%)
Cardiogenic shock 70/103 (68.0) 90/1908 (4.7) <0.001
Death 36/103 (35.0) 46/1928 (2.4) <0.001
Catecholamine administration 83/103 (80.6) 137/1911 (7.2) <0.001
Invasive or non-invasive ventilation 93/103 (90.3) 205/1911 (10.7) <0.001
aLeft ventricular ejection fraction (%): information from catheterization or echocardiography, if both available: catheterization.
bIncluding upper limits of the normal range for Troponin T, high sensitivity Troponin T, and Troponin I.
cIncluding upper limits of the normal range for brain natriuretic peptide and the N-terminal of prohormone brain natriuretic peptide.
BNP, brain natriuretic peptide; CA, cardiac arrest; ECG, electrocardiogram; IQR, inter-quartile range; LVEDP, left ventricular end-diastolic pressure; LVEF, left ventricular ejec-
tion fraction; TIA, transient ischaemic attack; TTS, takotsubo syndrome; ULN, upper limit of the normal range.
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..patients with and without life-threatening arrhythmias who survived
hospitalization.8
The use of devices (e.g. pacemakers) did not yield a substantial sur-
vival benefit, although our study was not designed to assess these
treatments. Stiermaier et al. have also not identified a prognostic ad-
vantage of implantable cardioverter defibrillators in TTS patients with
life-threatening arrhythmias, although they indicated a potential ad-
vantage of pacemakers in patients with bradyarrhythmias in the acute
phase.7
Multivariable analysis of the predictors of mortality after CA
showed that acute intracranial haemorrhage was independently asso-
ciated with unfavourable outcomes, while female sex was associated
....................................................................................................................................................................................................................
Table 2 Characteristics of takotsubo patients with cardiac arrest
Patients with CA at
initial presentation
Patients with CA during
the acute phase
Characteristic N5 84 N5 19 P-value
Demographics
Female sex, no./total no. (%) 71/84 (84.5) 14/19 (73.7) 0.26
Age (years) 61.3 ± 15.3 (N= 84) 64.9 ± 12.4 (N= 19) 0.35
Symptoms and triggers, no./total no. (%)
Chest pain 19/59 (32.2) 8/16 (50.0) 0.19
Dyspnoea 22/60 (36.7) 7/14 (50.0) 0.36
Physical trigger 52/84 (61.9) 10/19 (52.6) 0.46
Emotional trigger 9/84 (10.7) 4/19 (21.1) 0.22
ECG findings
Sinus rhythm on admission, no./total no. (%) 56/71 (78.9) 15/19 (78.9) 0.99
ST-segment elevation on admission, no./total no. (%) 24/71 (33.8) 14/19 (73.7) 0.003
ST-segment depression on admission, no./total no. (%) 10/71 (14.1) 2/19 (10.5) 0.69
T-wave inversion on admission, no./total no. (%) 25/71 (35.2) 7/19 (36.8) 0.90
Corrected QT on admission (ms) 478.7 ± 48.3 (N= 63) 460.6 ± 39.2 (N= 18) 0.11
Corrected QT at the event (ms) 478.7 ± 48.3 (N= 63) 468.6 ± 39.2 (N= 18) 0.28
Imaging and haemodynamic findings
Apical type, no./total no. (%) 67/84 (79.8) 17/19 (89.5) 0.32
LVEF (%)a 33.7 ± 9.7 (N= 78) 32.8 ± 10.3 (N= 18) 0.60
Heart rate (beats/min) 90.6 ± 22.8 (N= 50) 94.2 ± 20.2 (N= 11) 0.49
Systolic blood pressure (mmHg) 113.3 ± 25.3 (N= 50) 114.9 ± 24.9 (N= 12) 0.73
LVEDP (mmHg) 20.6 ± 8.1 (N= 60) 25.5 ± 7.2 (N= 8) 0.15
Neurologic and psychiatric disorders, no./total no. (%)
Acute neurologic disorders 11/80 (13.8) 2/17 (11.8) 0.83
Past or chronic neurologic disorders 17/77 (22.1) 3/17 (17.6) 0.69
Acute psychiatric disorders 6/80 (7.5) 2/17 (11.8) 0.56
Past or chronic psychiatric disorders 28/77 (36.4) 3/17 (17.6) 0.17
Cardiac biomarkers, median (IQR)
Troponin admission, factor increase in ULNb 5.94 (1.97–15.65) N= 64 8.20 (3.10–37.07) N= 15 0.38
Troponin maximum, factor increase in ULNb 11.22 (5.03–46.06) N= 68 27.90 (9.13–43.23) N= 16 0.31
Creatine kinase admission, factor increase in ULN 0.85 (0.45–1.47) N= 62 1.49 (0.82–3.20) N= 14 0.06
Creatine kinase maximum, factor increase in ULN 1.71 (0.70–5.44) N= 66 2.09 (0.99–3.26) N= 15 0.82
BNP admission, factor increase in ULNc 3.68 (1.05–5.40) N= 21 28.57 (1.71–95.20) N= 8 0.11
BNP maximum, factor increase in ULNc 5.25 (3.07–10.69) N= 29 41.11 (10.55–160.51) N= 10 <0.001
In-hospital complications and management, no./total no. (%)
Cardiogenic shock 59/84 (70.2) 11/19 (57.9) 0.30
Death 27/84 (32.1) 9/19 (47.4) 0.21
Catecholamine administration 68/84 (81.0) 15/19 (78.9) 0.84
Invasive or non-invasive ventilation 77/84 (91.7) 16/19 (84.2) 0.32
aLeft ventricular ejection fraction (%): information from catheterization or echocardiography, if both available: catheterization.
bIncluding upper limits of the normal range for Troponin T, high sensitivity Troponin T, and Troponin I.
cIncluding upper limits of the normal for brain natriuretic peptide and the N-terminal of prohormone brain natriuretic peptide.
BNP, brain natriuretic peptide; CA, cardiac arrest; ECG, electrocardiogram; IQR, inter-quartile range; LVEDP, left ventricular end-diastolic pressure; LVEF, left ventricular ejec-
tion fraction; ULN, upper limit of the normal range.
Cardiac arrest in takotsubo syndrome 2147
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..with a more benign clinical course. Another study has reported a
higher risk of CA in male TTS patients, but a clear-cut explanation for
this finding is lacking.20 T-wave inversion on admission was associated
with increased mortality following CA. As T-wave inversion has been
associated with myocardial oedema,10,24 the early appearance of T-
wave inversion may imply earlier or more extended oedema in the
acute phase. Myocardial oedema is also associated with QTc pro-
longation, which is associated with adverse events (e.g. ventricular
arrhythmias, mortality) in not only TTS but also other conditions like
coronary artery disease and dilated cardiomyopathy.10,25–28
Polymorphic VT is a potential mechanism of CA in TTS patients with
QTc prolongation.5,12,26 Thus, myocardial oedema may be the patho-
physiological mechanism underlying increased mortality after CA in
the presence of T-wave inversion.29
In patients with CA at TTS onset, TTS might be a consequence
of the stress associated with CA and/or CPR.30,31 Left ventricular
dysfunction can occur after CA; however, global hypokinesia is the
more frequent alteration, and TTS-like patterns occur in few CA
patients.32,33 Based on the current data, it is not possible to distin-
guish whether TTS is the cause or the consequence of CA, although
the former explanation is more likely.34,35 Conditions other than
TTS that could explain CA were not identifiable in the current ana-
lysis, but a systematic screening for rare causes, such as channelopa-
thies, was not performed.36 Hence, it is likely that a substantial
proportion of these events was caused by TTS, as a causal relation-
ship between TTS and life-threatening arrhythmias has already
been established. Most of our patients had CA at presentation,
which is consistent with previous reports.5,8 A potential explan-
ation for the relationship between TTS and CA is that TTS onset is
associated with massive increases in circulating catecholamine lev-
els, which together with myocardial stunning and oedema, may lead
to life-threatening arrhythmias.37 Compared with patients with CA
at presentation, those with CA during the acute phase were more
likely to have PEA/asystole, higher BNP values, and ST-segment ele-
vation on admission. This suggests that CA may develop in the
acute phase due to severely compromised heart function, whereas
a more purely arrhythmic substrate may lead to CA at presenta-
tion, which was often associated with VF/pulseless VT. Another
study has reported a similar distribution of CA at presentation vs.
during the acute phase (60 vs. 17 patients) and more frequent ven-
tricular tachyarrhythmias rather than PEA/asystole in CA at presen-
tation.5 However, that study was a systematic review of case
reports, and hence, relevant reporting and selection biases should
be acknowledged. In our study, patients with CA during the acute
phase showed a trend towards higher mortality compared with
patients with CA at initial presentation. Out-of-hospital CA was
not associated with higher mortality than in-hospital CA. These
interesting results should be investigated in future studies, even
though mortality is probably underestimated in patients with CA at
initial presentation. This is because TTS can only be diagnosed in
patients arriving alive and in condition to undergo imaging exams in
the emergency department. Cardiac arrest patients who die before
undergoing testing could never receive a diagnosis of TTS.
In the small subset of 19 patients who developed CA after initial
presentation, we identified that AF on admission, ST-segment eleva-
tion, and high C-reactive protein were univariably associated with
higher CA frequency, whereas female sex was associated with lower
CA frequency. ST-segment elevation might be associated with elec-
trical instability and may indicate the transmural extension of myocar-
dial oedema. Thus, TTS patients with these features at admission
merit intensive monitoring for about 48–72 h, given that the median
time to CA was 1 day (IQR, 0–3 days).
Study limitations
The study involved a partly retrospective analysis from a multicentre
registry. Therefore, potential confounding and selection biases must
Figure 2 Landmark survival analysis showing a significantly higher mortality rate in patients with cardiac arrest during the first 60 days (P< 0.001)
and during the 5-year follow-up (P< 0.001). TTS, takotsubo syndrome.
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..be considered when evaluating the results. Given the low number of
absolute events, the multivariable model for predictors of 60-day
mortality was based on few covariates that might have an impact on
the outcome. Data on left ventricular outflow tract obstruction,38
time to return of spontaneous circulation, and neurologic outcomes
after CPR were unavailable.
Conclusions
Cardiac arrest is relatively common in TTS and is associated with
worse outcomes. Cardiac arrest typically occurs at presentation, but
may occur in the subsequent acute phase. Clinical and electrocardio-
graphic parameters may independently predict mortality after CA
Figure 3 Univariable (A) and multivariable (B) predictors of 60-day mortality in patients with cardiac arrest (CA) and known initial heart rhythm.
Acute intracranial haemorrhage and T-wave inversion are independently associated with an increased risk of 60-day mortality after CA, whereas fe-
male sex is associated with a decreased risk. Black: statistically significant predictors; grey: not significant. BNP, brain natriuretic peptide; CI, confidence
interval; HR, hazard ratio; LVEF, left ventricular ejection fraction; TIA, transient ischaemic attack; ULN, upper limit of normal range; WBC, white
blood cell count.
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..and identify patients at a higher risk for developing CA in the acute
phase.
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Supplementary material is available at European Heart Journal online.
Funding
C.T. has been supported by the H.H. Sheikh Khalifa bin Hamad Al-Thani
Research Programme and the Swiss Heart Foundation. The InterTAK
Registry is supported by the Biss Davies Charitable Trust. The funding
source had no role in the study design and execution; data collection,
management, analysis, and interpretation; manuscript preparation, re-
view, and approval; or decision to submit the manuscript for publication.
Conflict of interest: Disclosures are reported by individual authors in
the ICMJE form as submitted to the editorial office.
References
1. Sato HTH, Uchida T, Dote K, Ishihara M. Tako-tsubo-like left ventricular dys-
function due to multivessel coronary spasm. In: K Kodama, K Haze, M Hori, eds.
Clinical Aspect of Myocardial Injury: From Ischemia to Heart Failure. Tokyo:
Kagakuhyoronsha Publishing; 1990. p56–64. (In Japanese.)
2. Di Vece D, Citro R, Cammann VL, Kato K, Gili S, Szawan KA, Micek J, Jurisic S,
Ding KJ, Bacchi B, Schwyzer M, Candreva A, Bossone E, D’Ascenzo F, Sarcon A,
Franke J, Napp LC, Jaguszewski M, Noutsias M, Mu¨nzel T, Knorr M, Heiner S,
Katus HA, Burgdorf C, Schunkert H, Thiele H, Bauersachs J, Tscho¨pe C, Pieske
BM, Rajan L, Michels G, Pfister R, Cuneo A, Jacobshagen C, Hasenfub G, Karakas
M, Koenig W, Rottbauer W, Said SM, Braun-Dullaeus RC, Banning A, Cuculi F,
Kobza R, Fischer TA, Vasankari T, Airaksinen KEJ, Opolski G, Dworakowski R,
MacCarthy P, Kaiser C, Osswald S, Galiuto L, Crea F, Dichtl W, Empen K, Felix
SB, Delmas C, Lairez O, El-Battrawy I, Akin I, Borggrefe M, Gilyarova E, Shilova
A, Gilyarov M, Horowitz J, Kozel M, Tousek P, Widimsky P, Winchester DE,
Ukena C, Di Mario C, Prasad A, Bo¨hm M, Bax JJ, Lu¨scher TF, Ruschitzka F,
Ghadri JR, Templin C. Outcomes associated with cardiogenic shock intakotsubo
syndrome. Circulation 2019;139:413–415.
3. Ghadri JR, Wittstein IS, Prasad A, Sharkey S, Dote K, Akashi YJ, Cammann VL,
Crea F, Galiuto L, Desmet W, Yoshida T, Manfredini R, Eitel I, Kosuge M, Nef
HM, Deshmukh A, Lerman A, Bossone E, Citro R, Ueyama T, Corrado D, Kurisu
S, Ruschitzka F, Winchester D, Lyon AR, Omerovic E, Bax JJ, Meimoun P,
Tarantini G, Rihal C, Y-Hassan S, Migliore F, Horowitz JD, Shimokawa H,
Lu¨scher TF, Templin C. International expert consensus document on takotsubo
syndrome (part II): diagnostic workup, outcome, and management. Eur Heart J
2018;39:2047–2062.
4. Templin C, Ghadri JR, Diekmann J, Napp LC, Bataiosu DR, Jaguszewski M,
Cammann VL, Sarcon A, Geyer V, Neumann CA, Seifert B, Hellermann J,
Schwyzer M, Eisenhardt K, Jenewein J, Franke J, Katus HA, Burgdorf C, Schunkert
H, Moeller C, Thiele H, Bauersachs J, Tscho¨pe C, Schultheiss HP, Laney CA,
Rajan L, Michels G, Pfister R, Ukena C, Bo¨hm M, Erbel R, Cuneo A, Kuck KH,
Jacobshagen C, Hasenfuss G, Karakas M, Koenig W, Rottbauer W, Said SM,
Braun-Dullaeus RC, Cuculi F, Banning A, Fischer TA, Vasankari T, Airaksinen KE,
Fijalkowski M, Rynkiewicz A, Pawlak M, Opolski G, Dworakowski R, MacCarthy
P, Kaiser C, Osswald S, Galiuto L, Crea F, Dichtl W, Franz WM, Empen K, Felix
SB, Delmas C, Lairez O, Erne P, Bax JJ, Ford I, Ruschitzka F, Prasad A, Lu¨scher
TF. Clinical features and outcomes of takotsubo (stress) cardiomyopathy. N Engl
J Med 2015;373:929–938.
103 With cardiac 
arrest and known 
initial heart 
rhythm / ECG
19 Patients with cardiac arrest in the 
acute phase
2098 Patients in the InterTAK Registry
170 With initial 
resuscitation / 
CPR due to 
absence of signs 
of circulation
1928 Without 
cardiac arrest
Prognostic predictors of 60-day mortality 
after cardiac arrest
5-year landmark analysis 
84 With cardiac arrest at presentation
Take home figure Cardiac arrest affects a relevant number of patients presenting with takotsubo syndrome and is associated with higher short
and long-term mortality. Although typically occurring at presentation, cardiac arrest can also occur in the subsequent acute phase in patients with
takotsubo syndrome. Among patients with cardiac arrest and takotsubo syndrome, simple clinical and electrocardiographic parameters may help to
identify those at higher risk of death.
2150 S. Gili et al.
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.5. Singh K, Carson K, Hibbert B, Le May M. Natural history of cardiac arrest in
patients with takotsubo cardiomyopathy. Am J Cardiol 2015;115:1466–1472.
6. Syed FF, Asirvatham SJ, Francis J. Arrhythmia occurrence with takotsubo cardio-
myopathy: a literature review. Europace 2011;13:780–788.
7. Stiermaier T, Rommel KP, Eitel C, Mo¨ller C, Graf T, Desch S, Thiele H, Eitel I.
Management of arrhythmias in patients with takotsubo cardiomyopathy: is
the implantation of permanent devices necessary? Heart Rhythm 2016;13:1979–1986.
8. El-Battrawy I, Lang S, Ansari U, Tu¨lu¨men E, Schramm K, Fastner C, Zhou X,
Hoffmann U, Borggrefe M, Akin I. Prevalence of malignant arrhythmia and sudden
cardiac death in takotsubo syndrome and its management. Europace 2018;20:
843–850.
9. Madias JE. Cardiac arrest-triggered takotsubo syndrome vs. takotsubo syndrome
complicated by cardiac arrest. Int J Cardiol 2016;225:142–143.
10. Madias C, Fitzgibbons TP, Alsheikh-Ali AA, Bouchard JL, Kalsmith B, Garlitski
AC, Tighe DA, Estes NA 3rd, Aurigemma GP, Link MS. Acquired long QT syn-
drome from stress cardiomyopathy is associated with ventricular arrhythmias
and torsades de pointes. Heart Rhythm 2011;8:555–561.
11. Migliore F, Zorzi A, Perazzolo Marra M, Iliceto S, Corrado D. Myocardial edema
as a substrate of electrocardiographic abnormalities and life-threatening arrhyth-
mias in reversible ventricular dysfunction of takotsubo cardiomypopathy: imaging
evidence, presumed mechanisms, and implications for therapy. Heart Rhythm
2015;12:1867–1877.
12. Stiermaier T, Eitel C, Denef S, Desch S, Schuler G, Thiele H, Eitel I. Prevalence
and clinical significance of life-threatening arrhythmias in takotsubo cardiomyop-
athy. J Am Coll Cardiol 2015;65:2148–2150.
13. Ghadri JR, Cammann VL, Templin C. The International Takotsubo Registry: ra-
tionale, design, objectives, and first results. Heart Fail Clin 2016;12:597–603.
14. Prasad A, Lerman A, Rihal CS. Apical ballooning syndrome (tako-tsubo or stress
cardiomyopathy): a mimic of acute myocardial infarction. Am Heart J 2008;155:
408–417.
15. Kleinman ME, Brennan EE, Goldberger ZD, Swor RA, Terry M, Bobrow BJ,
Gazmuri RJ, Travers AH, Rea T. Part 5: adult basic life support and cardiopul-
monary resuscitation quality: 2015 American Heart Association Guidelines up-
date for cardiopulmonary resuscitation and emergency cardiovascular care.
Circulation 2015;132:S414–S435.
16. Myerburg RJ, Halperin H, Egan DA, Boineau R, Chugh SS, Gillis AM, Goldhaber JI,
Lathrop DA, Liu P, Niemann JT, Ornato JP, Sopko G, Van Eyk JE, Walcott GP,
Weisfeldt ML, Wright JD, Zipes DP. Pulseless electric activity: definition, causes, mech-
anisms, management, and research priorities for the next decade: report from a
National Heart, Lung, and Blood Institute workshop. Circulation 2013;128:2532–2541.
17. Piccini JP, Allen LA, Kudenchuk PJ, Page RL, Patel MR, Turakhia MP; American
Heart Association Electrocardiography and Arrhythmias Committee of the
Council on Clinical Cardiology and Council on Cardiovascular and Stroke
Nursing. Wearable cardioverter-defibrillator therapy for the prevention of sud-
den cardiac death: a science advisory from the American heart association.
Circulation 2016;133:1715–1727.
18. Priori SG, Blomstro¨m-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J,
Elliott PM, Fitzsimons D, Hatala R, Hindricks G, Kirchhof P, Kjeldsen K, Kuck KH,
Hernandez-Madrid A, Nikolaou N, Norekva˚l TM, Spaulding C, Van Veldhuisen
DJ. 2015 ESC Guidelines for the management of patients with ventricular
arrhythmias and the prevention of sudden cardiac death: the Task Force for the
Management of Patients with Ventricular Arrhythmias and the Prevention of
Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed
by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur
Heart J 2015;36:2793–2867.
19. Wang Y, Xia L, Shen X, Han G, Feng D, Xiao H, Zhai Y, Chen X, Miao Y, Zhao
C, Wang Y, Guo M, Li T, Zhu HY. A new insight in sudden cardiac death in
young people—a systematic review of cases of takotsubo cardiomyopathy.
Medicine 2015;94:e1174.
20. Pant S, Deshmukh A, Mehta K, Badheka AO, Tuliani T, Patel NJ, Dabhadkar K,
Prasad A, Paydak H. Burden of arrhythmias in patients with takotsuo cardiomy-
opathy (Apical Ballooning Syndrome). Int J Cardiol 2013;170:64–68.
21. Ancona F, Bertoldi LF, Ruggieri F, Cerri M, Magnoni M, Beretta L, Cianflone D,
Camici PG. Takotsubo cardiomyopathy and neurogenic stunned myocardium:
similar albeit different. Eur Heart J 2016;7:2830–2832.
22. Napp LC, Ku¨hn C, Bauersachs J. ECMO in cardiac arrest and cardiogenic shock.
Herz 2017;42:27–44.
23. Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes.
Heart 2003;89:1363–1372.
24. Zorzi A, Perazzolo Marra M, Migliore F, De Lazzari M, Tarantini G, Iliceto S,
Corrado D. Relationship between repolarization abnormalities and myocardial
edema in atypical tako-tsubo syndrome. J Electrocardiol 2013;46:348–351.
25. Imran TF, Rahman I, Dikdan S, Shah R, Niazi OT, Thirunahari N, Alhaj E, Klapholz
M, Gaziano JM, Djousse L. QT prolongation and clinical outcomes in patients with
takotsubo cardiomyopathy. Pacing Clin Electrophysiol 2016;39:607–611.
26. Samuelov-Kinori L, Kinori M, Kogan Y, Swartzon M, Shalev H, Guy D, Ferenidou
F, Mashav N, Sadeh B, Atzmony L, Kliuk-Ben-Basat O, Steinvil A, Justo D.
Takotsubo cardiomyopathy and QT interval prolongation: who are the patients
at risk for torsades de pointes? J Electrocardiol 2009;42:353–357.
27. Williams ES, Thomas KL, Broderick S, Shaw LK, Velazquez EJ, Al-Khatib SM,
Daubert JP. Race and gender variation in the QT interval and its association with
mortality in patients with coronary artery disease: results from the Duke
Databank for Cardiovascular Disease (DDCD). Am Heart J 2012;164:434–441.
28. Karatolios K, Holzendorf V, Richter A, Schieffer B, Pankuweit S; Competence
Network Heart Failure Germany. Long-term outcome and predictors of out-
come in patients with non-ischemic dilated cardiomyopathy. Int J Cardiol 2016;
220:608–612.
29. Madias JE. Takotsubo syndrome/QTc interval prolongation/myocardial edema/
cardiac sympathetic denervation/cardiac arrhythmias: a quintet needing explor-
ation. Int J Cardiol 2016;203:259–261.
30. Wortsman J, Frank S, Cryer PE. Adrenomedullary response to maximal stress in
humans. Am J Med 1984;77:779–784.
31. Paradis NA, Martin GB, Rosenberg J, Rivers EP, Goetting MG, Appleton TJ,
Feingold M, Cryer PE, Wortsman J, Nowak RM. The effect of standard- and high-
dose epinephrine on coronary perfusion pressure during prolonged cardiopul-
monary resuscitation. JAMA 1991;265:1139–1144.
32. Kern KB, Hilwig RW, Rhee KH, Berg RA. Myocardial dysfunction after resuscita-
tion from cardiac arrest: an example of global myocardial stunning. J Am Coll
Cardiol 1996;28:232–240.
33. Cha KC, Kim HI, Kim OH, Cha YS, Kim H, Lee KH, Hwang SO. Echocardio-
graphic patterns of postresuscitation myocardial dysfunction. Resuscitation 2018;
124:90–95.
34. Madias JE. Cardiac arrest in patients before and after the inception of takotsubo
syndrome. Am J Cardiol 2015;115:1785.
35. Liang JJ, Cha YM, Oh JK, Prasad A. Sudden cardiac death: an increasingly recog-
nized presentation of apical ballooning syndrome (takotsubo cardiomyopathy).
Heart Lung 2013;42:270–272.
36. Prystowsky EN, Padanilam BJ, Joshi S, Fogel RI. Ventricular arrhythmias in the ab-
sence of structural heart disease. J Am Coll Cardiol 2012;59:1733–1744.
37. Wittstein IS, Thiemann DR, Lima JA, Baughman KL, Schulman SP, Gerstenblith G,
Wu KC, Rade JJ, Bivalacqua TJ, Champion HC. Neurohumoral features of myocar-
dial stunning due to sudden emotional stress. N Engl J Med 2005;352:539–548.
38. Templin C, Ghadri JR, Napp LC. Takotsubo (stress) cardiomyopathy. N Engl J
Med 2015;373:2689–2691.
Cardiac arrest in takotsubo syndrome 2151
